UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

-

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 28, 2023

4. т Ъ .

Common Stock, par value \$0.0001 per share DRMA The Nasdaq Ca Warrants, exercisable for one share of Common DRMAW The Nasdaq Ca Stock Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40) Securities Exchange Act of 1934 (17 CFR §240.12b-2).	(Exact na	ame of registrant as specified in its charter	er)
of Incorporation) File Number) Identification No.) 3525 Del Mar Heights Rd., #322 San Diego, CA 92130 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 800-2543. N/A (Former name or former address, if changed since last report) No.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the follow Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14d-2(b)) Securities registered pursuant to Section 12(b) of the Act: Trading Symbol Name of Each Exchange Car Mark Warrants, exercisable for one share of Common Stock, par value \$0.0001 per share DRMA The Nasdaq Ca Stock Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §240.42). Emerg If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not securities Exchange Act of 1934 (17 CFR §240.12b-2).	Delaware	001-40739	86-3218736
San Diego, CA 92130 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (658) 800-2543 (Zip Code) <i>N/A</i> (Former name or former address, if changed since last report) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the follow Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14d-2(b)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Trading Symbol Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMA Stock The Nasdaq Ca Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.400: Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerg If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comp			
Registrant's telephone number, including area code: (858) 800-2543. N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the follow Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) iecurities registered pursuant to Section 12(b) of the Act: Title of Each Class: Trading Symbol Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMAW Stock The Nasdaq Ca mdicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §240.42e). Emerg Emerg f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not period period for complexing wi	0		
N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the follow Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Trading Symbol Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMA Stock The Nasdaq Ca ndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR \$230.40) iecurities Exchange Act of 1934 (17 CFR \$240.12b-2). Emerg f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not prevent to the securities act of prevent to the securities act of prevent to act of prevent to the securities act of prevent to act of prevent to act of the securities act of prevent to act of the securitie	(Address of principal executive offices)		(Zip Code)
(Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the follow Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Trading Symbol Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMA Stock The Nasdaq Ca Micate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40) Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerg f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any norther securities and the registrant has elected not to use the extended transition period for complying with any norther securities and the registrant has elected not to use the extended transition period for complying with any norther securities and the registrant has elected not to use the extended transition period for complying	Registrant's telepl	hone number, including area code: (858)	800-2543
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: <u>Title of Each Class:</u> <u>Trading Symbol</u> Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMA Stock The Nasdaq Ca mdicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR \$230.40: Securities Exchange Act of 1934 (17 CFR \$240.12b-2). Emerg f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not securities action for the securities action for complying with any not securities action	(Former name		report)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Execurities registered pursuant to Section 12(b) of the Act: Title of Each Class: Trading Symbol Name of Each Exchange Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMAW Stock The Nasdaq Ca ndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40): Emerging arowth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complying with any not set the extended transition period for complyin	ck the appropriate box below if the Form 8-K filing is intended to si	imultaneously satisfy the filing obligation	n of the registrant under any of the following provisions:
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: <u>Title of Each Class:</u> <u>Trading Symbol</u> Name of Each Exchange Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMAW Stock The Nasdaq Ca Maticate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40) Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not set to the securities and the registrant has elected not to use the extended transition period for complying with any not set to the securities and the registrant has elected not to use the extended transition period for complying with any not set to the set the set to the set the set to the set of th	Written communications pursuant to Rule 425 under the Securities	s Act (17 CFR 230.425)	
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: <u>Title of Each Class:</u> <u>Trading Symbol</u> Common Stock, par value \$0.0001 per share DRMA Warrants, exercisable for one share of Common DRMAW Stock DRMAW ndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40) Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging with any not securities and the registrant is an emerging in the registrant in the registrant is an emerg	Soliciting material pursuant to Rule 14a-12 under the Exchange Ad	ct (17 CFR 240.14a-12)	
Image: Construction of the construc	Pre-commencement communications pursuant to Rule 14d-2(b) un	der the Exchange Act (17 CFR 240.14d-	2(b))
Securities registered pursuant to Section 12(b) of the Act: Trading Symbol Name of Each Exchang Common Stock, par value \$0.0001 per share DRMA The Nasdaq Ca Warrants, exercisable for one share of Common DRMAW The Nasdaq Ca Stock DRMAW The Nasdaq Ca ndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40: Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not securities for complying with any not	Pre-commencement communications pursuant to Rule 13e-4(c) un	der the Exchange Act (17 CFR 240 13e-	4(c))
Common Stock, par value \$0.0001 per share DRMA The Nasdaq Ca Warrants, exercisable for one share of Common DRMAW The Nasdaq Ca Stock DRMAW The Nasdaq Ca ndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40) Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any marked and the securities and t	• • • • • • • • • • • • • • • • • • • •		
Warrants, exercisable for one share of Common DRMAW The Nasdaq Ca Stock The Nasdaq Ca Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.40) Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any mark in the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the registrant has elected not to use the extended transition period for complying with any mark if the regist			Name of Each Exchange on which Registered
Exchange Act of 1934 (17 CFR §240.12b-2). Emerg f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any n	Varrants, exercisable for one share of Common		The Nasdaq Capital Market The Nasdaq Capital Market
f an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any m		company as defined in Rule 405 of the	Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of th
			Emerging growth company
			ansition period for complying with any new or revised financia

Item 8.01 Other Events.

As previously reported, on June 17, 2022, Dermata Therapeutics, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that based upon the closing bid price of the Company's common stock, par value \$0.0001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of \$1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). On December 15, 2022, the Company received a letter from the Staff of Nasdaq that the Company had been granted a 180-day extension through June 12, 2023, to regain compliance with the Minimum Bid Price Requirement.

On March 28, 2023, the Company received a letter from the Staff of Nasdaq indicating that the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DERMATA THERAPEUTICS, INC.

Dated: March 28, 2023

By: /s/ Gerald T. Proehl

Gerald T. Proehl Chief Executive Officer